{"count": 22, "results": [{"_id": "2550641", "pmid": 2550641, "title": "Clinical experience with lisinopril. Observations on safety and tolerability.", "journal": "J Hum Hypertens", "authors": ["Cameron HA", "Higgins TJ"], "date": "1989-06-01T00:00:00Z", "meta_date_publication": "1989 Jun", "meta_volume": "3 Suppl 1", "meta_issue": "", "meta_pages": "177-86", "score": 50069.586, "text_hl": "Fifty-three CHF @SPECIES_9606 @@@patients@@@ @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@died@@@ (9.1%) and in three cases @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@death@@@ was considered to be related to @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ therapy. ", "citations": {"NLM": "Cameron HA, Higgins TJ. Clinical experience with lisinopril. Observations on safety and tolerability. J Hum Hypertens. 1989 Jun;3 Suppl 1():177-86. PMID: 2550641", "BibTeX": "@article{2550641, title={Clinical experience with lisinopril. Observations on safety and tolerability.}, author={Cameron HA and Higgins TJ}, journal={J Hum Hypertens}, volume={3 Suppl 1}, pages={177-86}}"}}, {"_id": "2442561", "pmid": 2442561, "title": "The safety and tolerability of lisinopril in clinical trials.", "journal": "J Cardiovasc Pharmacol", "authors": ["Rush JE", "Merrill DD"], "date": "1987-01-01T00:00:00Z", "doi": "10.1097/00005344-198700003-00023", "meta_date_publication": "1987", "meta_volume": "9 Suppl 3", "meta_issue": "", "meta_pages": "S99-107", "score": 50066.14, "text_hl": "The percent of CHF @SPECIES_9606 @@@patients@@@ discontinuing because of an adverse clinical experience was 7.4%; the most frequent causes for discontinuation were @DISEASE_Hypotension @DISEASE_MESH:D007022 @@@hypotension@@@, @DISEASE_Dizziness @DISEASE_MESH:D004244 @@@dizziness@@@, or @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@renal impairment@@@. Twelve @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@deaths@@@ occurred in 311 CHF @SPECIES_9606 @@@patients@@@ treated with @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ (3.9%) compared to 4/104 (3.8%) of CHF @SPECIES_9606 @@@patients@@@ treated with placebo and 2/65 (3.1%) treated with @CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@. ", "citations": {"NLM": "Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol. 1987;9 Suppl 3():S99-107. PMID: 2442561", "BibTeX": "@article{2442561, title={The safety and tolerability of lisinopril in clinical trials.}, author={Rush JE and Merrill DD}, journal={J Cardiovasc Pharmacol}, volume={9 Suppl 3}, pages={S99-107}}"}}, {"_id": "8117550", "pmid": 8117550, "title": "Post-marketing surveillance of lisinopril in general practice in the UK.", "journal": "Br J Clin Pract", "authors": ["Fallowfield JM", "Blenkinsopp J", "Raza A", "Fowkes AG", "Higgins TJ", "Bridgman KM"], "date": "1993-11-01T00:00:00Z", "meta_date_publication": "1993 Nov-Dec", "meta_volume": "47", "meta_issue": "6", "meta_pages": "296-304", "score": 50064.805, "text_hl": "During the study, 1.5% of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ assigned to @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@died@@@ compared with 1.8% of @SPECIES_9606 @@@patients@@@ assigned to @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@, and 15.1% of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ @SPECIES_9606 @@@patients@@@ compared with 19.7% of @SPECIES_9606 @@@patients@@@ in the @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@ group withdrew because of adverse events. ", "citations": {"NLM": "Fallowfield JM, Blenkinsopp J, Raza A, Fowkes AG, Higgins TJ, Bridgman KM. Post-marketing surveillance of lisinopril in general practice in the UK. Br J Clin Pract. 1993 Nov-Dec;47(6):296-304. PMID: 8117550", "BibTeX": "@article{8117550, title={Post-marketing surveillance of lisinopril in general practice in the UK.}, author={Fallowfield JM and Blenkinsopp J and Raza A and Fowkes AG and Higgins TJ and Bridgman KM}, journal={Br J Clin Pract}, volume={47}, number={6}, pages={296-304}}"}}, {"_id": "7807512", "pmid": 7807512, "title": "Mortality matters.", "journal": "J Hum Hypertens", "authors": ["Hansson L"], "date": "1994-09-01T00:00:00Z", "meta_date_publication": "1994 Sep", "meta_volume": "8 Suppl 1", "meta_issue": "", "meta_pages": "S31-4", "score": 50061.812, "text_hl": "Moreover, @SPECIES_9606 @@@patients@@@ with @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@congestive heart failure@@@ have been shown to benefit from treatment with angiotensin converting enzyme (ACE) inhibitors as regards total @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@mortality@@@. The most recent addition to our knowledge stems from the GISSI-3 trials in which @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, alone or in combination with @CHEMICAL_Nitrates @CHEMICAL_MESH:D009566 @@@nitrates@@@, was shown to reduce @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@mortality@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@acute myocardial infarction@@@.", "citations": {"NLM": "Hansson L. Mortality matters. J Hum Hypertens. 1994 Sep;8 Suppl 1():S31-4. PMID: 7807512", "BibTeX": "@article{7807512, title={Mortality matters.}, author={Hansson L}, journal={J Hum Hypertens}, volume={8 Suppl 1}, pages={S31-4}}"}}, {"_id": "12652106", "pmid": 12652106, "title": "High dose lisinopril in heart failure: economic considerations.", "journal": "Cardiovasc Drugs Ther", "authors": ["Ess SM", "Lüscher TF", "Szucs TD"], "date": "2002-07-01T00:00:00Z", "doi": "10.1023/a:1021794229020", "meta_date_publication": "2002 Jul", "meta_volume": "16", "meta_issue": "4", "meta_pages": "365-71", "score": 50060.613, "text_hl": "High doses of the @GENE_ACE @GENE_1636 @@@angiotensin-converting enzyme@@@ (@GENE_ACE @GENE_1636 @@@ACE@@@) inhibitor @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ have been shown to significantly reduce the risk of @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@death@@@ or hospitalization for @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ and for any reason. ", "citations": {"NLM": "Ess SM, Lüscher TF, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc Drugs Ther. 2002 Jul;16(4):365-71. PMID: 12652106", "BibTeX": "@article{12652106, title={High dose lisinopril in heart failure: economic considerations.}, author={Ess SM and Lüscher TF and Szucs TD}, journal={Cardiovasc Drugs Ther}, volume={16}, number={4}, pages={365-71}}"}}, {"_id": "10852646", "pmid": 10852646, "title": "Lisinopril: a review of its use in congestive heart failure.", "journal": "Drugs", "authors": ["Simpson K", "Jarvis B"], "date": "2000-05-01T00:00:00Z", "doi": "10.2165/00003495-200059050-00012", "meta_date_publication": "2000 May", "meta_volume": "59", "meta_issue": "5", "meta_pages": "1149-67", "score": 50058.906, "text_hl": "Compared with recipients of low doses, those receiving high doses of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ had an 8% lower risk of all-cause mortality (p = 0.128), a 12% lower risk of @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@death@@@ or hospitalisation for any reason (p = 0.002) and 24% fewer hospitalisations for @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ (p = 0.002). ", "citations": {"NLM": "Simpson K, Jarvis B. Lisinopril: a review of its use in congestive heart failure. Drugs. 2000 May;59(5):1149-67. PMID: 10852646", "BibTeX": "@article{10852646, title={Lisinopril: a review of its use in congestive heart failure.}, author={Simpson K and Jarvis B}, journal={Drugs}, volume={59}, number={5}, pages={1149-67}}"}}, {"_id": "2442560", "pmid": 2442560, "title": "Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study.", "journal": "J Cardiovasc Pharmacol", "authors": ["Chalmers JP", "West MJ", "Cyran J", "De La Torre D", "Englert M", "Kramar M", "Lewis GR", "Maranhao MF", "Myburgh DP", "Schuster P"], "date": "1987-01-01T00:00:00Z", "doi": "10.1097/00005344-198700003-00021", "meta_date_publication": "1987", "meta_volume": "9 Suppl 3", "meta_issue": "", "meta_pages": "S89-97", "score": 50056.28, "text_hl": "Four @SPECIES_9606 @@@patients@@@ in the @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ group and three in the placebo group @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@died@@@ in this study, and there were 31 adverse clinical experiences in the 87 @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@-treated @SPECIES_9606 @@@patients@@@ compared to 13 in the 43 placebo-treated @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, Lewis GR, Maranhao MF, Myburgh DP, Schuster P. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol. 1987;9 Suppl 3():S89-97. PMID: 2442560", "BibTeX": "@article{2442560, title={Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study.}, author={Chalmers JP and West MJ and Cyran J and De La Torre D and Englert M and Kramar M and Lewis GR and Maranhao MF and Myburgh DP and Schuster P}, journal={J Cardiovasc Pharmacol}, volume={9 Suppl 3}, pages={S89-97}}"}}, {"_id": "18215613", "pmid": 18215613, "title": "Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial.", "journal": "Am Heart J", "authors": ["Pedrazzini G", "Santoro E", "Latini R", "Fromm L", "Franzosi MG", "Mocetti T", "Staszewsky L", "Barlera S", "Tognoni G", "Maggioni AP", "GISSI-3 Investigators"], "date": "2008-02-01T00:00:00Z", "doi": "10.1016/j.ahj.2007.10.015", "meta_date_publication": "2008 Feb", "meta_volume": "155", "meta_issue": "2", "meta_pages": "388-94", "score": 50055.027, "text_hl": "The beneficial effects of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ observed at 6 weeks (8 fewer @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@deaths@@@ per 1000 treated @SPECIES_9606 @@@patients@@@) were maintained up to nearly 5 years (10 fewer @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@deaths@@@ per 1000). ", "citations": {"NLM": "Pedrazzini G, Santoro E, Latini R, Fromm L, Franzosi MG, Mocetti T, Staszewsky L, Barlera S, Tognoni G, Maggioni AP, GISSI-3 Investigators. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. Am Heart J. 2008 Feb;155(2):388-94. PMID: 18215613", "BibTeX": "@article{18215613, title={Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial.}, author={Pedrazzini G and Santoro E and Latini R and Fromm L and Franzosi MG and Mocetti T and Staszewsky L and Barlera S and Tognoni G and Maggioni AP and GISSI-3 Investigators}, journal={Am Heart J}, volume={155}, number={2}, pages={388-94}}"}}, {"_id": "8891468", "pmid": 8891468, "title": "Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.", "journal": "Drugs", "authors": ["Goa KL", "Balfour JA", "Zuanetti G"], "date": "1996-10-01T00:00:00Z", "doi": "10.2165/00003495-199652040-00011", "meta_date_publication": "1996 Oct", "meta_volume": "52", "meta_issue": "4", "meta_pages": "564-88", "score": 50052.24, "text_hl": "Compared with no @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ treatment, reductions of 11% in risk of mortality and 7.7% in a combined end-point (@<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@death@@@ plus severe @DISEASE_Ventricular_Dysfunction_Left @DISEASE_MESH:D018487 @@@left ventricular dysfunction@@@) were evident at 6 weeks. ", "citations": {"NLM": "Goa KL, Balfour JA, Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs. 1996 Oct;52(4):564-88. PMID: 8891468", "BibTeX": "@article{8891468, title={Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.}, author={Goa KL and Balfour JA and Zuanetti G}, journal={Drugs}, volume={52}, number={4}, pages={564-88}}"}}, {"_id": "7910229", "pmid": 7910229, "title": "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.", "journal": "Lancet", "date": "1994-05-07T00:00:00Z", "meta_date_publication": "1994 May 7", "meta_volume": "343", "meta_issue": "8906", "meta_pages": "1115-22", "score": 50052.11, "text_hl": "GISSI-3: effects of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and transdermal @CHEMICAL_Nitroglycerin @CHEMICAL_MESH:D005996 @@@glyceryl trinitrate@@@ singly and together on 6-week @<m>DISEASE_Death</m> @DISEASE_MESH:D003643 @@@mortality@@@ and ventricular function after @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@acute myocardial infarction@@@. ", "citations": {"NLM": "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994 May 7;343(8906):1115-22. PMID: 7910229", "BibTeX": "@article{7910229, title={GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.}, journal={Lancet}, volume={343}, number={8906}, pages={1115-22}}"}}]}